Sigríður Gunnarsdóttir

Dr. Sigríður Gunnarsdóttir


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2017 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
VSValgerdur Sigurdardottir
Valgerdur Sigurdardottir
MKMarianne Kloke
Marianne Kloke
LRLukas Radbruch
Lukas Radbruch
RSRainer Sabatowski
Rainer Sabatowski
PKPål Klepstad
Pål Klepstad

4 January 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
GAGudlaug Helga Asgeirsdottir
Gudlaug Helga Asgeirsdottir
ESEinar Sigurbjörnsson
Einar Sigurbjörnsson
RTRannveig Traustadottir
Rannveig Traustadottir
VSValgerdur Sigurdardottir
Valgerdur Sigurdardottir
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
EKEwan Kelly
Ewan Kelly

1 October 2017 in International Journal of Nursing Studies
Verified
Journal Article
Closed access
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
SZSigridur Zoëga
Sigridur Zoëga
RSRonald C. Serlin
Ronald C. Serlin
HSHerdis Sveinsdottir
Herdis Sveinsdottir
EHElin Johanna Gudrun Hafsteinsdottir
Elin Johanna Gudrun Hafsteinsdottir
SWSandra Evelyn Ward
Sandra Evelyn Ward

22 December 2023 in JMIR Formative Research
Verified
Journal Article
Open access
NFNanna Fridriksdottir
Nanna Fridriksdottir
BIBrynja Ingadottir
Brynja Ingadottir
KSKristin Skuladottir
Kristin Skuladottir
SZSigridur Zoëga
Sigridur Zoëga
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
Background: Digital supportive cancer care is recommended to improve patient outcomes. A portal was designed and embedded within the electronic medical record and public health portal of Iceland, consisting of symptom and needs monitoring, educational material, and messaging. Objective: This study aims to assess (1) portal feasibility (adoption, engagement, usability, and acceptability), (2) potential predictors of usability and acceptability, and (3) the potential impact of the portal on patient-reported outcomes. Methods: This was a single-arm, before-and-after feasibility study at a university hospital among patients with cancer who were undergoing chemotherapy. Participation included filling out the Edmonton Symptom Assessment System–Revised (ESASr) weekly and the Distress Thermometer and Problem List (DT&PL) 3 times; reading educational material and messaging; and completing study questionnaires. Clinical and portal engagement data were collected from medical records. Data from patients were collected electronically at baseline and 7 to 10 days after the third chemotherapy round. Usability was assessed using the System Usability Scale (score 0-100), and acceptability was assessed using a 35-item survey (score 1-5). Patient-reported outcome measures included ESASr and DT&PL; a single-item scale for quality of life, family support, and quality of care; and multi-item scales for health literacy (Brief Health Literacy Screener), health engagement (Patient Health Engagement Scale), self-care self-efficacy (Self-Care Self-Efficacy scale), symptom interference (MD Anderson Symptom Inventory), knowledge expectations (Hospital Patients’ Knowledge Expectations), and received knowledge (Hospital Patients’ Received Knowledge). Health care professionals were interviewed regarding portal feasibility. Results: The portal adoption rate was 72% (103/143), and the portal use rate was 76.7% (79/103) over a mean 8.6 (SD 2.7) weeks. The study completion rate was 67% (69/103). The combined completion rate of the ESASr and DT&PL was 78.4% (685/874). Patients received a mean 41 (SD 13) information leaflets; 33% (26/79) initiated messaging, 73% (58/79) received messages, and 85% (67/79) received follow-up phone calls. The mean System Usability Scale score was 72.3 (SD 14.7), indicating good usability. Usability was predicted by age (β=−.45), ESASr engagement (β=.5), symptom interference (β=.4), and received knowledge (β=.41). The mean acceptability score, 3.97 (SD 0.5), was above average and predicted by age (β=−.31), ESASr engagement (β=.37), symptom interference (β=.60), self-care self-efficacy (β=.37), and received knowledge (β=.41). ESASr scores improved for total symptom distress (P=.003; Cohen d=0.36), physical symptoms (P=.01; Cohen d=0.31), and emotional symptoms (P=.01; Cohen d=0.31). Daily symptom interference increased (P=.03; Cohen d=0.28), quality of life improved (P=.03; Cohen d=0.27) and health engagement (P=.006; Cohen d=0.35) improved, while knowledge expectations decreased (P≤.001; Cohen d=2.57). Health care professionals were positive toward the portal but called for clearer role delineation and follow-up. Conclusions: This study supports the feasibility of a support portal and the results indicate the possibility of improving patient outcomes, but further developments are warranted.

27 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SASigríður Ása Alfonsdóttir
Sigríður Ása Alfonsdóttir
HJHarpa Lind Hjördísar Jónsdóttir
Harpa Lind Hjördísar Jónsdóttir
GÞGuðfinna Halla Þorvaldsdóttir
Guðfinna Halla Þorvaldsdóttir
SESigrún Elva Einarsdóttir
Sigrún Elva Einarsdóttir
Jóhanna Eyrún TorfadóttirJóhanna Eyrún Torfadóttir
Jóhanna Eyrún Torfadóttir
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
Background/Objectives: With improved technology and cancer treatments, the number of cancer survivors is growing. However, many cancer survivors experience long-term effects of cancer and its treatment, leading to a high health burden and poorer quality of life (QoL). A growing body of literature has explored the relationship between sociodemographic variables and QoL among cancer patients, although findings remain mixed. This study aims to assess the impact of social factors—role functioning, social functioning and social support—on the QoL of Icelandic cancer survivors diagnosed between 2015 and 2019, stratified by gender and cancer type (breast, prostate and colorectal cancer). Method: This study is a secondary analysis study, using data from a cross-sectional study conducted by the Icelandic Cancer Society in 2020–2021. In total, 1200 cancer survivors participated. Results: Multiple regression showed that less depressive symptoms, higher role and social functioning, better instrumental social support, higher educational attainment and income, less financial difficulties and lower age were significantly associated with higher QoL among participants. Conclusions: cancer survivors’ global health status/QoL is highly influenced by role functioning and depression symptoms, while other predictive factors, including social functioning, social support, education and income, vary by gender and cancer type.

8 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
KSKristjana Sigurðardóttir
Kristjana Sigurðardóttir
NFNanna Fridriksdottir
Nanna Fridriksdottir
NKNanna Kristinsdottir
Nanna Kristinsdottir
LKLára Kristjánsdóttir
Lára Kristjánsdóttir
HSHjalti Gunnlaugur Skúlason
Hjalti Gunnlaugur Skúlason
SGSigríður Gunnarsdóttir
Sigríður Gunnarsdóttir
Background: Population-based studies using patient-reported outcomes provide important insights into health-related quality of life (HRQoL) and the long-term impact of cancer and its treatment. Declining response rates and potential non-response bias have presented methodological challenges, particularly in registry-based surveys including both cancer survivors and population controls. The SURV-ICE study was established to assess HRQoL and health literacy among cancer survivors in Iceland while evaluating recruitment processes and participation patterns in a nationwide mixed-mode survey. Methods: SURV-ICE is a nationwide, population-based cross-sectional survey conducted in Iceland in 2025. Adults diagnosed with invasive cancer between 2014 and 2024 were identified through the Icelandic Cancer Registry and invited alongside an age- and gender-matched control group sampled from national registers. Participants completed validated EORTC instruments. Recruitment used a mixed-mode strategy including postal invitations, web-based and paper questionnaires, electronic reminders via the national health portal, and targeted telephone follow-up. Results: Among 10,005 cancer survivors 5489 (54.9%) responded to the questionnaires and among 5663 controls 2297 (40.6%) responded to the questionnaires. In both groups participation peaked among individuals aged 60–79 years and was lowest among the youngest and oldest groups. Cancer survivors had higher odds of participation than controls (OR 1.84; 95% CI 1.72–1.97). Most responses followed the initial postal invitation and first electronic reminder. Data completeness was high (≥80% item completion in 95.7% of instruments). Conclusions: Nationwide registry-based recruitment for large-scale PRO research is feasible in Iceland and can achieve competitive response rates without incentives. SURV-ICE provides an infrastructure for future research on cancer survivorship, HRQoL, and health literacy.